# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN
- Date: 2026-02-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Harriet Okonjo-Bell, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for establishing care for high blood pressure found at a workplace screening, morning headaches and protein in the urine at last year's executive physical, in a company founder who travels most weeks. **S**

## Objective

Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 25 mmol/L; Creatinine: 1.22 mg/dL (high); Glucose: 94 mg/dL; eGFR (CKD-EPI 2021, race-free): 54 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 286 mg/g (high); Hemoglobin A1c: 5.4%; Total cholesterol: 250 mg/dL (high); LDL cholesterol: 174 mg/dL (high); HDL cholesterol: 46 mg/dL (low); Triglycerides: 150 mg/dL (high); Hemoglobin: 12.4 g/dL; TSH: 1.9 mIU/L; PHQ-9: 4. All results are synthetic.

BP 166/102 mmHg; pulse 82 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 79 kg; BMI 29.7 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Elevated blood pressure at intake (166/102 mmHg, average of two readings), first found at a workplace screening; ambulatory monitoring to confirm; Albumin in the urine (urine albumin-to-creatinine ratio 286 mg/g) with eGFR 54 by the race-free CKD-EPI 2021 equation; she recalls protein in the urine at an executive physical a year ago, and those records are requested; to be repeated and investigated; Hyperlipidemia: LDL 174 mg/dL; 10-year ASCVD risk 7.9% by the Pooled Cohort Equations (intermediate). Strengths and supports remain part of the care plan. **S**

## Medication changes

- No medication changes. **S**

## Plan

- Nephrology consultation at the two-week visit for albuminuria and a reduced eGFR found at 49: the likely cause, whether more tests or a biopsy are needed, kidney-protective treatment, APOL1 testing, and monitoring that fits her travel. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Confirm the diagnosis outside the office: 24-hour ambulatory monitoring on a day at home, and a validated upper-arm home monitor with a correctly sized cuff that travels with her, two readings morning and evening for seven days, travel days included; recheck in two weeks. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Kidney evaluation: repeat urine albumin and creatinine at two weeks, compared with last year's results to establish chronicity; urinalysis; kidney ultrasound; calcium, phosphate, parathyroid hormone and 25-hydroxyvitamin D at baseline; every eGFR reported by the race-free CKD-EPI 2021 equation; no ibuprofen or naproxen. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021); A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Heart and vascular risk: ECG at intake and an echocardiogram for the left ventricular hypertrophy it shows; a fundus examination; TSH and A1c at diagnosis; lipid panel and 10-year ASCVD risk by the Pooled Cohort Equations. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018); CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026) **S**
- Food: sodium under 2 g a day built on what she eats, not a new diet: a salt-free seasoning blend for the dishes she cooks on Sundays, smoked turkey in small amounts in place of salt pork, ordering strategies for banquets and restaurants, water instead of a third coffee on travel days; video sessions with a registered dietitian between trips; no potassium-based salt substitutes until her kidney tests and any new medicines are settled. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Work and rest on her terms: she sets her schedule; the risks of uncontrolled blood pressure and kidney disease are stated plainly and any medicines are chosen to do the work, timed to her home clock across time zones, with a written sick-day card for her bag; a protected sleep window on travel nights and walking during layovers; video visits between trips and laboratory checks on her days at home. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Mood and stress: PHQ-9 at intake and yearly. Guideline: CMID: Clinical Monitoring Intelligence Database, hypertension, chronic kidney disease, hyperlipidemia and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**
- Vaccines: influenza today; pneumococcal, hepatitis B and Tdap needs reviewed at the preventive visit; influenza and COVID-19 each autumn. Guideline: Adult Immunization Schedule by Age (2026) **S**
